These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

510 related items for PubMed ID: 22640180

  • 1. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.
    Geisler CH, Kolstad A, Laurell A, Jerkeman M, Räty R, Andersen NS, Pedersen LB, Eriksson M, Nordström M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E, Nordic Lymphoma Group.
    Br J Haematol; 2012 Aug; 158(3):355-62. PubMed ID: 22640180
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study.
    Decaudin D, Brousse N, Brice P, Haioun C, Bourhis JH, Morel P, Van Hoof A, Souleau B, Quesnel B, Gisselbrecht C.
    Bone Marrow Transplant; 2000 Feb; 25(3):251-6. PubMed ID: 10673695
    [Abstract] [Full Text] [Related]

  • 3. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
    Vose JM.
    Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients.
    Dreger P, Martin S, Kuse R, Sonnen R, Glass B, Kröger N, Parwaresch R, Kneba M, Schmitz N, Haas R.
    Hematol J; 2000 Jun; 1(2):87-94. PubMed ID: 11920175
    [Abstract] [Full Text] [Related]

  • 10. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.
    Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, Smedby KE, Husby S, Pedersen LB, Andersen NS, Eriksson M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Workman CT, Garde C, Elonen E, Brown P, Grønbaek K, Geisler CH.
    Br J Haematol; 2016 Nov; 175(3):410-418. PubMed ID: 27378674
    [Abstract] [Full Text] [Related]

  • 11. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
    Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, Szymczyk M, Bouabdallah R, Kneba M, Hallek M, Salles G, Feugier P, Ribrag V, Birkmann J, Forstpointner R, Haioun C, Hänel M, Casasnovas RO, Finke J, Peter N, Bouabdallah K, Sebban C, Fischer T, Dührsen U, Metzner B, Maschmeyer G, Kanz L, Schmidt C, Delarue R, Brousse N, Klapper W, Macintyre E, Delfau-Larue MH, Pott C, Hiddemann W, Unterhalt M, Dreyling M, European Mantle Cell Lymphoma Network.
    Lancet; 2016 Aug 06; 388(10044):565-75. PubMed ID: 27313086
    [Abstract] [Full Text] [Related]

  • 12. Long-term follow-up of tandem high-dose therapy with autologous stem cell support for adults with high-risk age-adjusted international prognostic index aggressive non-Hodgkin Lymphomas: a GOELAMS pilot study.
    Monjanel H, Deconinck E, Perrodeau E, Gastinne T, Delwail V, Moreau A, François S, Berthou C, Gyan E, Milpied N, GOELAMS.
    Biol Blood Marrow Transplant; 2011 Jun 06; 17(6):935-40. PubMed ID: 21109011
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi.
    Merli F, Luminari S, Ilariucci F, Petrini M, Visco C, Ambrosetti A, Stelitano C, Caracciolo F, Di Renzo N, Angrilli F, Carella AM, Capodanno I, Barbolini E, Galimberti S, Federico M.
    Br J Haematol; 2012 Feb 06; 156(3):346-53. PubMed ID: 22145911
    [Abstract] [Full Text] [Related]

  • 19. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
    Liu HW, Seftel MD, Rubinger M, Szwajcer D, Demers A, Nugent Z, Schroeder G, Butler JB, Cooke A.
    Int J Radiat Oncol Biol Phys; 2010 Oct 01; 78(2):513-20. PubMed ID: 20137862
    [Abstract] [Full Text] [Related]

  • 20. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
    Wang EH, Chen YA, Corringham S, Bashey A, Holman P, Ball ED, Carrier E.
    Bone Marrow Transplant; 2004 Oct 01; 34(7):581-7. PubMed ID: 15273714
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.